论文部分内容阅读
目的比较瑞舒伐他汀与阿托伐他汀对冠心病急性心肌梗死患者血管内皮功能的影响。方法选取自2012年10月—2014年10月收治的120例冠心病心肌梗死患者,随机将其分为A、B两组,各60例。患者均接受急性心肌梗死的基础对症处理。A组患者接受瑞舒伐他汀药物方案,B组给予阿托伐他汀方案,坚持治疗6个月,比较不同药物方案对冠心病急性心肌梗死患者血管内皮功能的影响。结果治疗前,2组患者血脂指标、血管内皮指标、血清一氧化氮(NO)、超敏C反应蛋白(hs-CRP)及左心射血分数(LVEF)对比差异无统计学意义(P>0.05);治疗后,A组患者TC、LDL-C值分别为(3.02±0.62)mmol/L、(1.41±0.70)mmol/L,血清NO、hs-CRP分别为(103.32±10.71)μmol、(2.05±0.56)mg/L,与B组相比差异显著(P<0.05);2组患者治疗期间不良反应发生率对比差异无统计学意义(P>0.05)。结论在冠心病急性心肌梗死患者的治疗中,采用瑞舒伐他汀与阿托伐他汀方案,2者在改善患者血管内皮功能、减轻炎症方面均有其疗效,近期疗效相似,且安全性高。但瑞舒伐他汀有更强的减轻炎症反应及降脂功能,值得推广。
Objective To compare the effects of rosuvastatin and atorvastatin on vascular endothelial function in patients with coronary heart disease with acute myocardial infarction. Methods From July 2012 to October 2014, 120 patients with CHD were enrolled and randomly divided into A and B groups, 60 cases each. Patients underwent symptomatic treatment of acute myocardial infarction. Patients in group A received rosuvastatin drug regimen, and group B received atorvastatin regimen for 6 months. The effects of different drug regimens on vascular endothelial function in patients with acute myocardial infarction with coronary heart disease were compared. Results Before treatment, there was no significant difference in the levels of serum lipids, vascular endothelial indexes, serum nitric oxide (NO), hs-CRP and LVEF between the two groups (P> 0.05). After treatment, the levels of TC and LDL-C in group A were (3.02 ± 0.62) mmol / L and (1.41 ± 0.70) mmol / L respectively, and the serum NO and hs-CRP were (103.32 ± 10.71) (2.05 ± 0.56) mg / L, which was significantly different from that in group B (P <0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). Conclusion In the treatment of patients with acute myocardial infarction with coronary heart disease, rosuvastatin and atorvastatin are used in the treatment of patients with coronary heart disease. Both of them have their curative effect in improving the vascular endothelial function and reducing the inflammation in patients with similar efficacy and safety. However, rosuvastatin has a stronger anti-inflammatory response and lipid-lowering function, it is worth promoting.